Literature DB >> 30593646

Mice with Chimeric Human Livers and Their Applications.

Donna N Douglas1, Norman M Kneteman2.   

Abstract

The complete life cycle of the hepatitis C virus (HCV) can be recapitulated in vivo using immunodeficient mice that have had their livers extensively repopulated with human hepatocytes. These human liver chimeric mouse models have enabled the study of many aspects of the HCV life cycle, including antiviral interventions that have helped to shape the curative landscape that is available today. The first human liver chimeric mouse model capable of supporting the HCV life cycle was generated in SCID-uPA mice. Although other human liver chimeric mouse models have since been developed, the SCID-uPA mouse model remains one of the most robust in vivo systems available for HCV studies. This chapter reviews development, validation and application of the SCID-uPA mouse model, and discusses their potential application for studying other liver-centric diseases and pathogens and for the design and testing of vaccine candidates for the eradication of HCV.

Entities:  

Keywords:  Animal models; Antiviral therapy; Pathology; Viral hepatitis

Mesh:

Substances:

Year:  2019        PMID: 30593646     DOI: 10.1007/978-1-4939-8976-8_32

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  3 in total

Review 1.  Liver regeneration biology: Implications for liver tumour therapies.

Authors:  Christopher Hadjittofi; Michael Feretis; Jack Martin; Simon Harper; Emmanuel Huguet
Journal:  World J Clin Oncol       Date:  2021-12-24

2.  Animal Models for Hepatitis B: Does the Supply Meet the Demand?

Authors:  Alexander Ploss; Hélène Strick-Marchand; Wenhui Li
Journal:  Gastroenterology       Date:  2021-03-06       Impact factor: 22.682

3.  A Role for B Cells to Transmit Hepatitis C Virus Infection.

Authors:  Isabelle Desombere; Freya Van Houtte; Ali Farhoudi; Lieven Verhoye; Caroline Buysschaert; Yvonne Gijbels; Sibyl Couvent; Wilfried Swinnen; Hans Van Vlierberghe; André Elewaut; Andrea Magri; Zania Stamataki; Philip Meuleman; Jane A McKeating; Geert Leroux-Roels
Journal:  Front Immunol       Date:  2021-12-16       Impact factor: 8.786

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.